Alendronic Acid
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Drug reference
Etelcalcetide
Calcium Supplement · Agent for secondary hyperparathyroidism
Also known as Etelcalcetide hydrochloride, Parsabiv
Calcium SupplementAgent for secondary hyperparathyroidism
CDSCO approvedSchedule H
EXCRETION
—
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
Manufacturer advises use only if potential
FDA category + note
Top interactionssee all 12 →
- Alendronic AcidSevereDatabaseDDInter
- AmifostineSevereDatabaseDDInter
- BumetanideSevereDatabaseDDInter
- CinacalcetSevereDatabaseDDInter
Mechanism
Etelcalcetide is a calcimimetic that activates the calcium-sensing receptor (CaSR). This activation, particularly in the parathyroid gland, leads to inhibition of parathyroid hormone (PTH) secretion.
Indications
Secondary hyperparathyroidism in patients with chronic kidney disease on haemodialysissecondary hyperparathyroidism in adults with chronic kidney disease (CKD) on dialysis
Dosing
- Adult
- ▶ BY MOUTH ▶ Adult: Initially 30 mg twice daily (max. per dose 90 mg 4 times a day), dose to be adjusted every 2–4 weeks according to response Hypocalcaemia Conditions that may worsen with a decrease in serum-calcium concentrations .…
Pharmacokinetics
Onset
plasma concentrations reach steady state approximately 8 weeks after thrice-weekly dosing
Half-life
3 to 5 days (in hemodialysis patients)
Excretion
cleared by renal excretion in patients with normal kidney function; hemodialysis is the predominant elimination pathway in patients receiving hemodialysis
Contraindications
- Hypocalcaemia
- initial serum calcium <8.4 mg/dL
Side effects
Common
Nausea
Serious
- Hypocalcaemia
- hypocalcemia
- lowered seizure threshold (with significant reductions in serum Ca2+)
- adynamic bone disease (if PTH level falls below 100 pg/mL)
- worsening of heart failure
- upper gastrointestinal bleeding
Pregnancy & lactation
Pregnancy
Manufacturer advises use only if potential
Drug interactions
Amifostine
Severe
Database
Clinical effect not specified
Source: DDInter
Bumetanide
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Cinacalcet
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Cisplatin
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Denosumab
Severe
Database
Clinical effect not specified
Source: DDInter
Etacrynic Acid
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Etidronic Acid
Severe
Database
Clinical effect not specified
Source: DDInter
Foscarnet
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Furosemide
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Ibandronate
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Pamidronic Acid
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Related guidelines
Chronic kidney disease — assessment and management
KDIGO · Nephrology · 2024
Dialysis — initiation and maintenance
ISN_INDIA · Nephrology · 2023
Acute kidney injury
KDIGO · Nephrology · 2012
Chronic kidney disease — assessment and management
NICE · Nephrology · 2021
Chronic kidney disease — mineral and bone disorder
KDIGO · Nephrology · 2017
Other Calcium Supplement drugs
Ask House about Etelcalcetide
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, BNF·Verified: 2026-05-13 · House clinical team